PRTN3 and rheumatoid arthritis: Since their discovery in 1964, ACPAs or anti-CCPs (anti-cyclic citrullinated peptides) have transformed RA diagnosis and the understanding of its pathophysiology such that tests for ACPA were incorporated into the 2010 American College of Rheumatology/European League Against Rheumatism diagnostic criteria [115,116].